This study aims to evaluate the clinical impact of PSMA-PET and FCH-PET on two groups of PC patients in BR with a PSA value ≤ 2 ng/mL imaged by either one of these radiopharmaceuticals, then treated with image-guided RT on the local or oligometastatic PC lesions detected. This evidence concerns the gene FOLH1 and pachyonychia congenita.